| 前收市價 | 5.75 |
| 開市 | 4.20 |
| 買盤 | 2.04 |
| 賣出價 | 5.30 |
| 拍板 | 965.00 |
| 到期日 | 2024-07-26 |
| 今日波幅 | 4.20 - 5.75 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 無 |
Motley FoolForget Eli Lilly: 3 Biotech Stocks to Buy Instead
Eli Lilly is a good stock to buy, but these should be even better.
Investor's Business DailyNovo, Lilly Tumble After Study Ties Blindness Disorder To Weight-Loss Drugs
Novo Nordisk stock skidded Wednesday after a new study suggests its diabetes and weight-loss drug can lead to a blindness-causing disease.
BloombergOzempic Linked to Rare Cases of Vision Loss in Harvard Study
(Bloomberg) -- Novo Nordisk A/S’ best-selling diabetes and weight-loss drugs Ozempic and Wegovy appear to be associated with a higher risk of a rare form of vision loss, according to an analysis by doctors at Massachusetts Eye and Ear, a Harvard-affiliated hospital.Most Read from BloombergUS Allies Say China Is Developing Attack Drones for RussiaChina Can End Russia’s War in Ukraine With One Phone Call, Finland SaysBiden Struggles to Contain Pressure to Abandon Reelection BidHouse Democrats Cons
